Institute of Genomic Medicine

Peter Tolias, Ph.D.

Titles:

Executive Director, Institute of Genomic Medicine
Professor of Pediatrics, UMDNJ-New Jersey Medical School
Adjunct Professor of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School

Background:

Dr. Tolias obtained his Ph.D. from McGill University in Canada , was a post-doctoral fellow at Harvard University and received Executive training at the Wharton Business School of University of Pennsylvania . He has previously served as Vice President of Worldwide Advanced Research, at Ortho-Clinical Diagnostics - a Johnson & Johnson company, one of the world's largest clinical diagnostic product development and manufacturing companies, where he was responsible for Technology Assessment, Discovery Research and Clinical Development of Biomarkers that support J&J therapeutic products. Dr. Tolias has also served as Executive Vice President of Corporate Development at Rosetta Genomics, a public biotechnology company focused in microRNA-based diagnostics and therapeutics. His role was to develop Global Strategy, lead Global Business Development and US Operations and assist the company towards their eventually successful IPO. Earlier in his career, Dr. Tolias was Founder and Director of the Center for Applied Genomics, an academic R&D center now part of the Institute of Genomic Medicine . He previously served as an Associate Professor of Microbiology & Molecular Genetics, UMDNJ-New Jersey Medical School , an Associate Member at the Public Health Research Institute and earlier as an Assistant Member.

Professional Interests and Activities:

Dr. Tolias's research interests are rooted in translational medicine, focused on the discovery, validation and commercial development of biomarkers that serve the clinical diagnostic and pharmaceutical markets. He is currently President of NeuroMark Inc., a privately-owned molecular diagnostic company focused on neurospsychiatric disorders. He is also the founder of several biotechnology companies, a consulting & capital sourcing firm specializing in the biotechnology sector and serves on multiple boards of directors/trustees . He has authored over 40 scientific publications and received dozens of grants, awards and honors.